Comparative Pharmacology
Head-to-head clinical analysis: SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH versus TRIMPEX 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH versus TRIMPEX 200.
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH vs TRIMPEX 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis. Together, they provide sequential blockade of folate metabolism, leading to bactericidal activity.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
1 double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for most infections; single-strength tablet (400 mg/80 mg) is used for prophylaxis: 1 tablet orally daily.
200 mg orally once daily, or 100 mg orally twice daily.
None Documented
None Documented
Sulfamethoxazole: 10-12 hours (prolonged in renal impairment); Trimethoprim: 8-11 hours (prolonged in hepatic impairment).
Terminal elimination half-life is 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Sulfamethoxazole: primarily renal (70-90% as unchanged drug and acetylated metabolite); Trimethoprim: renal (50-60% unchanged, rest as metabolites); small biliary/fecal elimination (<5% each).
Renal excretion of unchanged drug accounts for approximately 60-80% of elimination, with an additional 10-20% as hepatic metabolites excreted in bile and feces.
Category D/X
Category C
Antibiotic
Antibiotic